Close Menu

NEW YORK – Point-of-care diagnostic firm ProciseDx announced Wednesday that its tests measuring levels of infliximab and adalimumab received CE marking for use on its ProciseDx immunoassay system.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.